Harrow Health 8625 Stock Net Asset
| HROWL Stock | USD 25.30 0.10 0.40% |
Fundamental analysis of Harrow Health allows traders to better anticipate movements in Harrow Health's stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Harrow Health 8625 Company Net Asset Analysis
Harrow Health's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Harrow Health Net Asset | 388.97 M |
Most of Harrow Health's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harrow Health 8625 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Harrow Health 8625 has a Net Asset of 388.97 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Harrow Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harrow Health's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harrow Health could also be used in its relative valuation, which is a method of valuing Harrow Health by comparing valuation metrics of similar companies.Harrow Health is currently under evaluation in net asset category among its peers.
Harrow Fundamentals
| Return On Equity | 0.45 | ||||
| Number Of Shares Shorted | 2.96 K | ||||
| Revenue | 199.61 M | ||||
| EBITDA | 19.28 M | ||||
| Net Income | (17.48 T) | ||||
| Total Debt | 228.83 M | ||||
| Cash Flow From Operations | (22.2 M) | ||||
| Market Capitalization | 247.48 M | ||||
| Total Asset | 388.97 M | ||||
| Retained Earnings | (151.38 T) | ||||
| Annual Yield | 0.09 % | ||||
| Net Asset | 388.97 M |
About Harrow Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harrow Health 8625's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harrow Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harrow Health 8625 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Harrow Health Piotroski F Score and Harrow Health Altman Z Score analysis. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Harrow Health 8625 is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.